Enabling access to new WHO essential medicines: the case for nicotine replacement therapies
- PMID: 21092092
- PMCID: PMC2994846
- DOI: 10.1186/1744-8603-6-22
Enabling access to new WHO essential medicines: the case for nicotine replacement therapies
Abstract
Nicotine replacement therapies (NRT) are powerful tools for the successful treatment of nicotine addiction and tobacco use. The medicines are clinically effective, supported by the Framework Convention on Tobacco Control, and are now World Health Organization-approved essential medicines. Enabling global access to NRT remains a challenge given ongoing confusion and misperceptions about their efficacy, cost-effectiveness, and availability with respect to other tobacco control and public health opportunities. In this commentary, we review existing evidence and guidelines to make the case for global access to NRT highlighting the smoker's right to access treatment to sensibly address nicotine addiction.
Figures
References
-
- World Health Organization (WHO) WHO report on the Global Tobacco Epidemic, 2008: The MPOWER package. WHO, Geneva; 2008.
-
- World Health Organization (WHO) 16th WHO Model List of Essential Medicines. http://www.who.int/selection_medicines/list/en/ Accessed: November 23, 2009.
-
- Fiore MC, Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2008.
-
- Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2008. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
